Johnson & Johnson is pumping more money into heart care with a roughly $13 billion deal for Shockwave Medical, which specializes in technology that helps open clogged arteries.
The health care giant said Friday that it will spend $335 in cash for each share of Shockwave. The total deal value includes cash acquired.
The deal has already been approved by the boards of directors from both companies.
Founded in 2009, Shockwave focuses on intravascular lithotripsy technology that uses sonic pressure waves to crack calcium lesions in arteries and restore blood flow. It’s similar to a technique used to break up kidney stones. The soundwave emitters are placed inside angioplasty catheters to reach the calcified areas of the artery.
Shockwave’s technology is used to treat coronary artery and peripheral artery disease.
The company’s revenue jumped 49% last year to $730 million.
Related articles:
Related suggestion:
Auckland Airport expects the population of a city during school holidaysCanada's Trudeau says he often mulls quitting his 'crazy job' but will stay onWeek in Politics: Truancy presents delicate problems for the governmentWeek in Politics: Truancy presents delicate problems for the governmentWest Coast meat processor admits water quality failureUS says China helping Moscow in biggest defence expansion since Soviet eraDaylight saving: When it ends, why we observe it and how to change the time on your phoneWatch: PM Christopher Luxon speaks at first postCoach speaks on car chase, gun shots after Hawke's Bay rugby gamePure Tūroa gets 10
2.6745s , 6497.9375 kb
Copyright © 2024 Powered by J&J to pump another $13B into its MedTech business with Shockwave deal ,World Wrap news portal